'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Medicamen Biotech Limited
MEDICAMEQ (NSE) · MEDICAMEQ (BSE 531146) · ISIN INE646B01010 · Pharmaceuticals · Est. 1993 · listed 2021 · website
ESM Stage 1 · NSE ESM Stage 1 · BSE
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹43.85 cr and profit after tax ₹2.53 cr. Revenue was 14% higher than in Q1 FY26.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹43.85 cr | ₹2.53 cr | 1.86 | 14 Aug 2026 |
| Q4 FY26 standalone | ₹54.68 cr | ₹2.97 cr | 2.19 | 27 May 2026 |
| Q3 FY26 standalone | ₹43.49 cr | ₹2.59 cr | 1.91 | 13 Feb 2026 |
| Q2 FY26 standalone | ₹42.23 cr | ₹2.21 cr | 1.63 | 14 Nov 2025 |
| Q1 FY26 standalone | ₹38.45 cr | ₹1.64 cr | 1.21 | 12 Aug 2025 |
| Q4 FY25 standalone | ₹26 cr | ₹2.41 cr | 1.90 | 30 May 2025 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹279.73 cr | ₹36.93 cr | ₹361.52 cr |
| 30 Sep 2025 standalone | ₹272.04 cr | ₹30.79 cr | ₹350.67 cr |
| 31 Mar 2025 standalone | ₹217.38 cr | ₹27.22 cr | ₹292.93 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 40.46% | 0.07% | 0.40% | 59.54% |
Latest filings
- Annual Report FY2025-26 (New) 3 September 2026 · BSE
- Annual Report FY2025-26 (New) 3 September 2026 · NSE
- Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 14 August 2026 · NSE
- Financial Results for the quarter ended on June 30, 2026. 14 August 2026 · BSE
- Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 27 May 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 3 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.